Cell-Based Therapies for Heart Failure

Antonio Carlos Campos de Carvalho; Tais H Kasai-Brunswick; Adriana Bastos Carvalho

doi:10.3389/fphar.2021.641116

Cell-Based Therapies for Heart Failure

Front Pharmacol. 2021 Apr 12:12:641116. doi: 10.3389/fphar.2021.641116. eCollection 2021.

Authors

Antonio Carlos Campos de Carvalho^{1

2

3}, Tais H Kasai-Brunswick^{2

3}, Adriana Bastos Carvalho^{1

3}

Affiliations

¹ Laboratory of Cellular and Molecular Cardiology, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
² National Center of Structural Biology and Bioimaging (CENABIO), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
³ National Institute of Science and Technology in Regenerative Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Abstract

Heart failure has reached epidemic proportions with the advances in cardiovascular therapies for ischemic heart diseases and the progressive aging of the world population. Efficient pharmacological therapies are available for treating heart failure, but unfortunately, even with optimized therapy, prognosis is often poor. Their last therapeutic option is, therefore, a heart transplantation with limited organ supply and complications related to immunosuppression. In this setting, cell therapies have emerged as an alternative. Many clinical trials have now been performed using different cell types and injection routes. In this perspective, we will analyze the results of such trials and discuss future perspectives for cell therapies as an efficacious treatment of heart failure.

Keywords: adult stem cells; bone marrow cells; cell therapies; heart failure; pluripotent cells (Min5–Max 8).